Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Songling Xuemaikang Capsule vs Losartan for Primary Hypertension
ChiCTR-IPR-16008108Phase 4Recruiting
- Sponsor
- Dongzhimen Hospital of Beijing University of Traditional Chinese Medicine
- Start
- Dec 2015
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of songling xuemaikang in essential hypertension (2 arms), sponsored by Dongzhimen Hospital of Beijing University of Traditional Chinese Medicine. Primary endpoint: SeDBP. Started Dec 2015; status: recruiting.
02
Drugs
songling xuemaikang
03
Conditions
essential hypertension
Beyond the preview
Go deeper on ChiCTR-IPR-16008108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-16008108.